The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year.
Earnings per share were -62¢, ahead of consensus on The Street, where analysts were looking for sales of $6.4 million.
“We believe V-Go has the potential to one day become the insulin delivery method of choice for millions of patients with Type 2 diabetes and that the revenue potential for Valeritas is substantial,” president & CEO John Timberlake said in prepared remarks. “Studies continue to show that patients with Type 2 diabetes who switched from insulin pens and syringes to V-Go not only significantly lowered their blood glucose, but did so with less insulin. Our record second-quarter revenue demonstrates the continued momentum of both awareness and adoption of V-Go among prescribing physicians as well as patients with type 2 diabetes.”
Valeritas said it expects to post sales of $26 million to $28 million for the full year.
VLRX shares were trading at $1.47 apiece today in afternoon activity, down -2%.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.